Barclays Lowers Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00
Avidity Biosciences (NASDAQ:RNA – Get Free Report) had its price target dropped by investment analysts at Barclays from $63.00 to $57.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price points to a potential upside of 86.03% from the stock’s current […]
More Stories
Macron Affirms Support for Greenland Sovereignty Amid US Interest in Annexation
By Rachel Roberts French President Emmanuel Macron has reaffirmed his support for the sovereignty of the Danish territory of Greenland...
DOJ Releases More Epstein Files, Says Some Documents Contain False Claims
By Jack Phillips The Department of Justice (DOJ) on Tuesday morning released thousands of documents related to the now-deceased convicted...
House Oversight Committee Expands Investigation Into Minnesota Fraud
By Jackson Richman The House Oversight Committee expanded its investigation into fraud in Minnesota on Dec. 22. The committee has...
US Economy Expands 4.3 Percent in 3rd Quarter, Topping Expectations
By Andrew Moran Robust consumer spending and a rebound in exports have helped the U.S. economy grow faster than economists...
Is A Man on the Inside Season 3 Confirmed? Everything We Know So Far
Upon the completion of Season 2 of the series A Man on the Inside, people started asking for the series’...
Top 10 Hottest Female Rappers in the World in 2026
Are you also interested in knowing who is the hottest and sexiest rapper in 2026 and where most of them...